Research programme: drug discovery - Novartis/Morphochem

Drug Profile

Research programme: drug discovery - Novartis/Morphochem

Latest Information Update: 15 Jul 2010

Price : $50

At a glance

  • Originator Morphochem AG
  • Class Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Unspecified

Most Recent Events

  • 01 Dec 2005 Morphochem AG has been acquired by Biovertis AG
  • 13 Jun 2005 The research agreement between Morphochem and Novartis has been successfully completed
  • 05 Dec 2003 Preclinical trials in Undefined in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top